Kedrion has activated a robust nationwide U.S. distribution network to support the commercial availability of QIVIGY, its FDA approved 10% Intravenous Immunoglobulin (IVIG) therapy. Kedrion’s distribution model is designed to provide broad access across specialty pharmacies, infusion centers, hospitals, and other sites of care nationwide, ensuring consistent supply and scalable reach as demand for IVIG therapies continues to grow.